The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer.
Geoffrey Yuyat Ku
No relevant relationships to disclose
Benjamin Haaland
No relevant relationships to disclose
Tatsuya Ioka
Research Funding - Chugai Pharma; Roche; Taiho Pharmaceutical; Yakult
Hiroyuki Isayama
No relevant relationships to disclose
Yousuke Nakai
No relevant relationships to disclose
Ann-Lii Cheng
No relevant relationships to disclose
Takuji Okusaka
No relevant relationships to disclose
Gilberto de Lima Lopes
Honoraria - Lilly; Taiho Pharmaceutical